1WEISS R B, DONEHOWER R C, WIERNIK P H, et al. Hypersensitivity reactions from taxol[J]. J Clin Oncol, 1990, 8 (7) : 1263-1268.
2TEN TIJE A J, VERWEIJ J, LOOS W J, et al. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy[J]. Clin Pharmacokinet, 2003, 42 (7) :665-685.
3GELDERBLOM H, VERWEIJ J, NOOTER K, et al. Cremophor EL:The drawbacks and advantages of vehicle selection for drug formulation [ J ]. Eur J Cancer, 2001, 37 ( 13 ) : 1590-1598.
4EMEA. Assessment report for Abraxane [ EB/OL]. (2010-07- 03 ) . http ://www. ema. europa.eu/humandocs/PDFs/EPAR/ abraxane/H-778-en6. pdf.
7State Food and Drug Administration, Center for Drug Evaluation. General Guidance for Development & Research of Chemical Drug Products [ EB/OL ] . (2009-12-17) http://www. cde. org. cn/ zdyz. do? method = largePage&id =2061.
10WANG H X ZHANG N.Pharmacology and toxicology evaluation of cytotoxic liposome products .中国新药杂志,2007,16(4):257-259.
同被引文献8
1D.OMalley,P.Gary,R.Salani,et al.Ohio state university,columbus,oh a phase II evaluation of carboplatin/paclitaxel/bevacizumab in the treatment of advanced-stage endometrial carcinoma:report of toxicity[J].Gynecol Oncolo,2011,120(S1):S33.
3Seiji Isonishi,Michiko Suzuki,Masanori Hirama,et al.Use of docetaxel after paclitaxel hypersensitivity reaction in epithelial ovarian and endometrial cancer clinic[J].Ovari Cance,2009,2(1):44-47.
4Toshiaki Sendo,Yoshinori Itoh,Takeshi Goromaru,et al.Role of substance P in Hypersensitivity reactions induced by paclitaxel an anticancer agent[J].Peptides,2004,25(7):1205-1208.
5Castells MC,Tennant NM,Matulonis UA.Hypersensitivity reactions to chemotherapy:outcomes and safety of rapid desensitization in 413 cases[J].J Allergy Clin Immunol,2008,122(3):574-580.
6Anna M.Feldweg,Chyh-Woei Lee,Ursula A.Matulonis,et al.Rapid desensitization for Hypersensitivity reactions to paclitaxel and docetaxel:a new standard protocol used in 77 successful treatments[J].Gynecolog Oncol,2005,96(3):824-829.
